Prelude Therapeutics
$4.91
19
+$0.00+0% Thursday 20:00
-$0.03-0.56%Thursday 21:26After hours
Statistics
Day High
4.91
Day Low
4.88
52W High
5.52
52W Low
0.78
Volume
10,799
Avg. Volume
-
Mkt Cap
391.06M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
19AugExpected
Expected EPS
-0.2375
Actual EPS
N/A
Financials
-819.59%Profit Margin
Unprofitable12.14MRevenue
-99.5MNet Income
Analyst Ratings
7.67Average Price Target
The highest estimate is 9.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy 67%
Hold 33%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow PRLD. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.41B
Novartis
NVS
Mkt Cap296.54B
Gilead Sciences
GILD
Mkt Cap158.77B
Bristol-Myers Squibb
BMY
Mkt Cap117.46B
AMGEN
AMGN
Mkt Cap193.39B
Merck
MRK
Mkt Cap317.77B
Pfizer
PFE
Mkt Cap138.44B
Regeneron Pharmaceuticals
REGN
Mkt Cap66.35B
About
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Show more...
CEO
Dr. Krishna Vaddi D.V.M., Ph.D.
Employees
131
Country
United States
ISIN
US74065P1012
Listings
0 Comments
Share your thoughts
FAQ
What is Prelude Therapeutics stock price today?▼
The current price of PRLD is $4.91 USD — it has increased by +0% in the past 24 hours. Watch Prelude Therapeutics stock price performance more closely on the chart.
What is Prelude Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Prelude Therapeutics stocks are traded under the ticker PRLD.
Is Prelude Therapeutics stock price growing?▼
PRLD stock has fallen by -0.41% compared to the previous week, the month change is a +28.87% rise, over the last year Prelude Therapeutics has showed a +518.39% increase.
What is Prelude Therapeutics market cap?▼
Today Prelude Therapeutics has the market capitalization of 391.06M
When is the next Prelude Therapeutics earnings date?▼
Prelude Therapeutics is going to release the next earnings report on August 19, 2026.
What were Prelude Therapeutics earnings last quarter?▼
PRLD earnings for the last quarter are -0.13 USD per share, whereas the estimation was -0.25 USD resulting in a +48.51% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Prelude Therapeutics revenue for the last year?▼
Prelude Therapeutics revenue for the last year amounts to 12.14M USD.
What is Prelude Therapeutics net income for the last year?▼
PRLD net income for the last year is -99.5M USD.
How many employees does Prelude Therapeutics have?▼
As of July 06, 2026, the company has 131 employees.
In which sector is Prelude Therapeutics located?▼
Prelude Therapeutics operates in the Health & Wellness sector.
When did Prelude Therapeutics complete a stock split?▼
Prelude Therapeutics has not had any recent stock splits.
Where is Prelude Therapeutics headquartered?▼
Prelude Therapeutics is headquartered in Wilmington, United States.